Vandortuzumab vedotin (DSTP 3086S) is an antibody-drug-conjugate to target prostate cancer.
Vandortuzumab vedotin (DSTP 3086S) is an antibody-drug-conjugate to target prostate cancer.
Vanicoside B targets cyclin-dependent kinase 8 (CDK8) and exhibits anti-tumor activity. The potential mechanism is Vanicoside B blocks CDK8-mediated signaling pathways and decreases the expression of epithelial-mesenchymal transition proteins, so that it leads to cell cycle arrest and apoptosis.
Vanin-1-IN-1 is an inhibitor of the vanin-1 enzyme. Vanin-1 is a cell surface-associated inositol (GPi) anchored protein that plays an important role in metabolism and inflammation.
Vanin-1-IN-1 is an inhibitor of the vanin-1 enzyme. Vanin-1 is a cell surface-associated inositol (GPi) anchored protein that plays an important role in metabolism and inflammation.
Vanin-1-IN-1 is an inhibitor of the vanin-1 enzyme. Vanin-1 is a cell surface-associated inositol (GPi) anchored protein that plays an important role in metabolism and inflammation.
Vanin-1-IN-1 is an inhibitor of the vanin-1 enzyme. Vanin-1 is a cell surface-associated inositol (GPi) anchored protein that plays an important role in metabolism and inflammation.
Vaniprevir (MK-7009) is a non-covalent competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease.
Vaniprevir (MK-7009) is a non-covalent competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease.